Waters Parkerson & Co’s GSK GSK Stock Holding History

Waters Parkerson & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$264K	Sell	5,034 -70	-1%	-$3.7K	0.01%	178
2026 Q1	$282K	Hold	5,104	–	–	0.01%	167
2025 Q4	$250K	Hold	5,104	–	–	0.01%	174
2025 Q3	$220K	Sell	5,104 -8,140	-61%	-$318K	0.01%	176
2025 Q2	$509K	Sell	13,244 -1,200	-8%	-$45.9K	0.03%	132
2025 Q1	$560K	Sell	14,444 -1,694	-10%	-$62K	0.03%	126
2024 Q4	$546K	Hold	16,138	–	–	0.03%	130
2024 Q3	$660K	Sell	16,138 -2,642	-14%	-$108K	0.03%	118
2024 Q2	$723K	Buy	18,780 +962	+5%	+$40.5K	0.04%	104
2024 Q1	$764K	Sell	17,818 -52	-0.3%	-$2.14K	0.04%	105
2023 Q4	$662K	Sell	17,870 -660	-4%	-$23.7K	0.04%	112
2023 Q3	$672K	Buy	18,530 +550	+3%	+$19.5K	0.04%	102
2023 Q2	$641K	Hold	17,980	–	–	0.04%	111
2023 Q1	$640K	Sell	17,980 -728	-4%	-$25.5K	0.04%	107
2022 Q4	$657K	Sell	18,708 -2,425	-11%	-$80.8K	0.04%	104
2022 Q3	$622K	Sell	21,133 -393	-2%	-$14.9K	0.04%	104
2022 Q2	$1.17M	Sell	21,526 -314	-1%	-$17.3K	0.07%	86
2022 Q1	$1.19M	Sell	21,840 -1,533	-7%	-$83.3K	0.07%	89
2021 Q4	$1.29M	Buy	23,373 +51	+0.2%	+$2.65K	0.07%	87
2021 Q3	$1.11M	Sell	23,322 -1,188	-5%	-$59.7K	0.06%	92
2021 Q2	$1.22M	Sell	24,510 -69,672	-74%	-$3.35M	0.07%	89
2021 Q1	$4.2M	Sell	94,182 -47,630	-34%	-$2.16M	0.26%	53
2020 Q4	$6.52M	Sell	141,812 -4,450	-3%	-$204K	0.44%	51
2020 Q3	$6.88M	Sell	146,262 -1,991	-1%	-$99.8K	0.52%	51
2020 Q2	$7.56M	Sell	148,253 -2,266	-2%	-$116K	0.61%	49
2020 Q1	$7.13M	Sell	150,519 -5,345	-3%	-$285K	0.69%	45
2019 Q4	$9.15M	Buy	155,864 +1,834	+1%	+$102K	0.69%	48
2019 Q3	$8.22M	Sell	154,030 -4,163	-3%	-$214K	0.66%	48
2019 Q2	$7.91M	Sell	158,193 -1,046	-0.7%	-$52.5K	0.64%	48
2019 Q1	$8.32M	Sell	159,239 -4,948	-3%	-$247K	0.7%	45
2018 Q4	$7.84M	Buy	164,187 +2,397	+1%	+$118K	0.76%	43
2018 Q3	$8.12M	Buy	161,790 +2,013	+1%	+$102K	0.66%	48
2018 Q2	$8.05M	Sell	159,777 -3,960	-2%	-$199K	0.69%	44
2018 Q1	$8M	Sell	163,737 -12,010	-7%	-$559K	0.7%	45
2017 Q4	$7.79M	Sell	175,747 -26,519	-13%	-$1.23M	0.66%	46
2017 Q3	$10.3M	Buy	202,266 +6,773	+3%	+$344K	0.91%	41
2017 Q2	$10.5M	Buy	195,493 +8,675	+5%	+$462K	0.97%	38
2017 Q1	$9.85M	Buy	186,818 +9,721	+5%	+$493K	0.93%	39
2016 Q4	$8.53M	Buy	177,097 +23,361	+15%	+$1.15M	0.86%	40
2016 Q3	$8.29M	Buy	153,736 +6,013	+4%	+$330K	0.85%	40
2016 Q2	$8M	Buy	147,723 +4,580	+3%	+$241K	0.86%	40
2016 Q1	$7.26M	Buy	143,143 +6,926	+5%	+$345K	0.8%	40
2015 Q4	$6.87M	Sell	136,217 -699	-0.5%	-$35.6K	0.79%	41
2015 Q3	$6.58M	Sell	136,916 -7,486	-5%	-$390K	0.84%	39
2015 Q2	$7.52M	Sell	144,402 -8,212	-5%	-$462K	0.88%	40
2015 Q1	$8.8M	Sell	152,614 -13,685	-8%	-$785K	1.03%	36
2014 Q4	$8.88M	Buy	166,299 +13,625	+9%	+$762K	1.05%	37
2014 Q3	$8.77M	Buy	152,674 +5,167	+4%	+$317K	1.05%	37
2014 Q2	$9.86M	Sell	147,507 -384	-0.3%	-$26K	1.18%	35
2014 Q1	$9.88M	Buy	147,891 +166	+0.1%	+$11.2K	1.22%	35
2013 Q4	$9.86M	Sell	147,725 -250	-0.2%	-$16.2K	1.21%	35
2013 Q3	$9.28M	Buy	147,975 +6,609	+5%	+$425K	1.25%	34
2013 Q2	$8.83M	Buy	+141,366	New	+$8.97M	1.28%	35

Other funds holding GSK

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EIC

Equity Investment Corp Atlanta, Georgia $5.24B AUM 11.32% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

MHI

Miller Howard Investments Kingston, New York $3.77B AUM 23.82% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Waters Parkerson & Co's GSK Position: Q2 2026 in Review

Waters Parkerson & Co reduced its GSK (GSK) stake by 1.4% in Q2 2026, selling an estimated $3.7K and leaving 5,034 shares worth $264K. The position accounts for 0.01% of the portfolio, ranked #178.

Waters Parkerson & Co first reported a position in GSK in Q2 2013 and has held it in 53 quarters since. The position peaked at $10.5M in Q2 2017. 628 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Waters Parkerson & Co held 5,034 shares of GSK worth $264K as of Q2 2026.
Waters Parkerson & Co sold 70 GSK shares in Q2 2026, an estimated $3.7K.
GSK made up 0.01% of Waters Parkerson & Co's portfolio in Q2 2026, its #178 holding.
Waters Parkerson & Co first reported a position in GSK in Q2 2013 and has held it in 53 quarters since.
Waters Parkerson & Co's GSK position peaked at $10.5M in Q2 2017.
628 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Waters Parkerson & Co's 13F filing for Q2 2026, filed 30 Jul 2026.